Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 549 tulemused
Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
The objectives of this pilot study were to evaluate the safety and efficacy of the central nervous system stimulant methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel.
METHODS
Patients with early breast cancer who presented asthenia >3 on the
Association between asthenia and nutritional status, lean body mass, anemia, psychological status, and tumor mass in patients with advanced breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Sixty-four consecutive patients with advanced breast cancer were included in a study designed to determine the prevalence of asthenia and its association with other clinical features. The Asthenia Score (AS, the average of four tests designed by our group to assess asthenia) was 59 +/- 9 for
Analysis of factors related to arm weakness in patients with breast cancer-related lymphedema.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
The aim of this study was to evaluate the ratio of significant weakness in the affected arm of breast cancer-related lymphedema patients to their unaffected side. Another purpose was to identify factors related to arm weakness and physical function in patients with breast cancer-related
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We
Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Muscle weakness and cachexia are significant paraneoplastic syndromes of many advanced cancers. Osteolytic bone metastases are common in advanced breast cancer and are a major contributor to decreased survival, performance, and quality of life for patients. Pathologic fracture caused by osteolytic
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do not revert bone destruction. In metastatic
[Determination of a vector of therapy for weakness in incurable breast cancer patients based on the level of inflammatory response].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The weakness is one of the negative factors that degrade cancer patients’ quality of life. The nature of weakness may be multifactorial but among mechanisms of development of weakness a syndrome of chronic inflammation plays a crucial role. Therapy aimed at reducing of inflammation degree allows
Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Several recently published studies describe moderate to severe cognitive dysfunction in breast cancer survivors who were treated with adjuvant chemotherapy 1-5 years before undergoing extensive neuropsychological testing. While these studies are hypothesis-generating and preliminary given their
Asthenia in breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
This article is a report of a review of the effectiveness of exercise programmes on shoulder mobility and lymphoedema in postoperative patients with breast cancer having axillary lymph node dissection, as revealed by randomized controlled trials.
BACKGROUND
Breast cancer is the most common
Breast cancer in European Union: an update of screening programmes as of March 2014 (review).
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Breast cancer, a major cause of female morbidity and mortality, is a global health problem; 2008 data show an incidence of ~450,000 new cases and 140,000 deaths (mean incidence rate 70.7 and mortality rate 16.7, world age-standardized rate per 100,000 women) in European Union Member States.
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study, patients were randomized to olaparib 10, 30, 100, 200 or 400 mg
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer.
METHODS
Patients with HER-2-negative disease who had received prior adjuvant anthracycline-based therapy received
Does architectural lighting contribute to breast cancer?
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
There is a growing interest in the role that light plays on nocturnal melatonin production and, perhaps thereby, the incidence of breast cancer in modern societies. The direct causal relationships in this logical chain have not, however, been fully established and the weakest link is an
Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
